Evidence map›Paper›PMID 30034543›Full record

ReviewTherapeutic advances in urology2018

The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Karl-Erik Andersson, Nurul Choudhury, Jean-Nicolas Cornu, Moses Huang, Cees Korstanje, Emad Siddiqui, Philip Van Kerrebroeck

Open access · bronzeAbstract readReview
In one paragraph

Review in Therapeutic advances in urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 6 countries.

Karl-Erik AnderssonInstitute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA Aarhus Institute for Advanced Sciences (AIAS), Aarhus University, Aarhus, Denmark.
Nurul ChoudhuryAstellas Pharma Europe Ltd., 2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, UK.
Jean-Nicolas CornuDepartment of Urology, Rouen University Hospital and University of Rouen, Rouen, France.
Moses HuangAstellas Pharma Europe Ltd., Chertsey, Surrey, UK.
Cees KorstanjeAstellas Pharma Europe Research and Development, Leiden, The Netherlands.
Emad SiddiquiAstellas Pharma Medical and Development, Leiden, The Netherlands.
Philip Van KerrebroeckMaastricht University Medical Centre, Maastricht, The Netherlands.
Astellas Pharma (Netherlands) · NLAstellas Pharma (United Kingdom) · GBAarhus University · DKInstitute for Research and Innovation in Biomedicine · FRMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urgency is the prevalent and most bothersome symptom of overactive bladder (OAB) and the treatment of urgency is the primary objective in the management of OAB. Urgency has a major impact on other symptoms of OAB and culminates in an increased frequency of micturition and reduced volume voided, which may contribute to shorter intervals between the need to void. Antimuscarinic agents and mirabegron, a β

Indexed as

antimuscariniccombination therapymirabegronoveractive bladderurgency

Identifiers

PMID30034543
PMCPMC6048625
OpenAlexW2847640005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.